Mutations in the CEBPA gene occur in 7–15% of all AML cases; the subgroup of biallelic CEBPA mutations in AML patients has now been acknowledged as a definite entity in the recent World Health Organization (WHO) classification, given its distinct biological and clinical features, as well as its prognostic significance [1]. Here, CEBPA is linked to acute myeloid leukemia.